News Disc Medicine, Inc.

Equities

IRON

US2546041011

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
29 ^USD	+1.65%		+9.35%	-49.79%

08/04	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT
02/04	Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	08/04	MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	02/04	MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating	02/04	MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating	02/04	MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating	02/04	MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept	02/04	MT
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Top Midday Decliners	01/04	MT
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	01/04	MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75	01/04	MT
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)	01/04	GL
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	01/04	CI
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating	21/03	MT
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03	GL
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating	12/03	MT
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024	07/03	GL
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	26/02	MT
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer	26/02	GL
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	26/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Disc Medicine, Inc.

Equities

IRON

US2546041011

Summary

Filters